PHYTOCHEMICAL STUDIES AND QUALITATIVE ANALYSIS BY TLC OF MURRAYA KOENIGII BARK EXTRACT

Murraya koenigii is a medium size, ever green plant which has been utilized as a source of food, medicine, and other agricultural purposes in different communities. Thus, the preliminary phytochemical analysis and TLC separation was done using methanol, n-hexane, and ethyl acetate(1:3:1), as solvent system while iodine vapour as spotting agent. The phytochemical screening of diethyl ether extracts of bark revealed the presence of carbohydrates , anthraquinones glycosides ,saponins ,flavanoids, and alkaloids, while chloroform extracts of bark revealed carbohydrates, tannins, saponins, and alkaloids, while acetone extracts of bark revealed the presence of carbohydrates, anthraquinones glycosides, flavanoids and alkaloids,while ethanol extracts of bark revealed the presence of carbohydrates, tannins, anthraquinones glycosides,s aponins, flavanoids and alkaloids.TLC separation showed (3) spots each of Diethyl Ether, Chloroform, Acetone, Ethanol from bark extracts. From our findings, it can be concluded that Murraya Koenigii contains some significant phytochemicals that can exhibit desired therapeutic activities such as Antioxidant, Anti-Microbial, Anti-Fungal, Anti-Diabetic, Anti-Ulcer and Cosmetic use. However, there is a need to conduct further Pharmaceutical Analysis on test extracts in order to establish these biomedical applications. Keywords: Thin Layer Chromatography, Murraya koenigii Bark, Phytochemical screening

Correlation of Sagittal Skeletal malocclusion and Growth patterns between Digital and Conventional Dermatoglyphics

Background: The craniofacial morphology and its growth pattern are determined by the influence of various environmental factors depending on the genetic background. Due to the close association of MSX 1 and SMARCAD gene on the same chromosome, it can be hypothesized that malocclusion and fingerprint pattern are related. Furthermore, it is observed that the orofacial structures originate from the same embryonic tissue as the epidermal ridges, which are the ectoderm. Thus, the simultaneous development of the epidermal ridges and the orofacial structure during this time is deciphered and reflected in the fingerprint patterns. Aim: This study aimed to analyse, compare, and correlate the fingerprint patterns of individuals with different skeletal malocclusions and growth patterns using manual and digital methods. Materials and Methods: Patients (a random sample of 544) who were undergoing orthodontic treatment and were able to give informed consent were included in the study. Informed consent was obtained prior to the start of the procedure, with due regard to ethical issues and the confidentiality of fingerprint records. The anteroposterior jaw relation was determined from the patient's lateral cephalogram with evaluation of the parameters: SNA, ANB, SNB and growth patterns are determined using the mandibular plane angle according to Steiners analysis, the nature of the growth patterns, i.e., horizontal (HGP), Average (AGP) and vertical (VGP) growth pattern. Results: Individuals with loop patterns had a frequency of skeletal class I malocclusion, Whorl patterns with skeletal class II malocclusion, and Arch patterns with skeletal class III malocclusion. Consistent with the growth patterns, the whorl pattern was seen more prominently in the horizontal growth pattern, Arch pattern in the average growth pattern, and the loop pattern in the vertical growth pattern. Conclusion: Thus, the dermatoglyphics can be used as a screening tool for early prediction of skeletal malocclusion in a younger age group

Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding

Background and Aim. Variceal bleeding is the second most important precipitating factor related to the development of episodic hepatic encephalopathy; but to date there are no recommendations to prevent this complication. The aim of this study was to compare if primary prophylaxis with lactulose or L-ornithine L-aspartate or rifaximin, in cirrhotic patients with variceal bleeding, is better than placebo for avoiding the development of hepatic encephalopathy. Methods. A randomized, double-blind, placebo-controlled clinical trial (ClinicalTrials.gov identifier: NCT02158182) which included cirrhotic patients with variceal bleeding, without minimal or clinical hepatic encephalopathy at admission. Findings. 87 patients were randomized to one of four groups. The basal characteristics were similar between groups. Comparatively with placebo, the frequency with regard to the development of hepatic encephalopathy was as follows: lactulose (54.5% versus 27.3%; OR = 0.3, 95% CI 0.09-1.0; P = 0.06); L-ornithine L-aspartate (54.5% versus 22.7%, OR = 0.2, 95% CI 0.06-0.88; P = 0.03); rifaximin (54.5% versus 23.8%; OR = 0.3, 95% CI 0.07-0.9; P = 0.04). There was no significant difference between the three groups receiving any antiammonium drug (P = 0.94). In the group receiving lactulose, 59.1% had diarrhea, and 45.5% had abdominal discomfort, bloating, and flatulence. Two patients (10%) treated with lactulose and a patient (4.5%) in the placebo group developed spontaneous bacterial peritonitis due to E. coli; one of them died due to recurrent variceal bleeding. There were no other adverse effects. Conclusions. Antiammonium drugs, particularly L-ornithine L-aspartate and rifaximin, proved to be effective in preventing the development of hepatic encephalopathy in those cirrhotic patients with variceal bleeding

Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study

BACKGROUND: In human immunodeficiency virus (HIV)-positive adults, low CD4 cell counts despite fully suppressed HIV-1 RNA on antiretroviral therapy (ART) have been associated with increased risk of morbidity and mortality. We assessed the prevalence and outcomes of poor immune response (PIR) in children receiving suppressive ART. METHODS: Sixteen cohorts from the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) contributed data. Children <18 years at ART initiation, with sustained viral suppression (VS) (≤400 copies/mL) for ≥1 year were included. The prevalence of PIR (defined as World Health Organization advanced/severe immunosuppression for age) at 1 year of VS was described. Factors associated with PIR were assessed using logistic regression. Rates of acquired immunodeficiency syndrome (AIDS) or death on suppressive ART were calculated by PIR status. RESULTS: Of 2318 children included, median age was 6.4 years and 68% had advanced/severe immunosuppression at ART initiation. At 1 year of VS, 12% had PIR. In multivariable analysis, PIR was associated with older age and worse immunological stage at ART start, hepatitis B coinfection, and residing in Thailand (all P ≤ .03). Rates of AIDS/death (95% confidence interval) per 100 000 person-years were 1052 (547, 2022) among PIR versus 261 (166, 409) among immune responders; rate ratio of 4.04 (1.83, 8.92; P < .001). CONCLUSIONS: One in eight children in our cohort experienced PIR despite sustained VS. While the overall rate of AIDS/death was low, children with PIR had a 4-fold increase in risk of event as compared with immune responders

Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study

International audienceIn human immunodeficiency virus (HIV)-positive adults, low CD4 cell counts despite fully suppressed HIV-1 RNA on antiretroviral therapy (ART) have been associated with increased risk of morbidity and mortality. We assessed the prevalence and outcomes of poor immune response (PIR) in children receiving suppressive ART